UNBX (Unity Biotechnology) Net Margin %: 0.00% (As of Mar. 2025)


What is Unity Biotechnology Net Margin %?

Unity Biotechnology UNBX Net Margin % is 0.00% as of Mar. 2025.

Net margin is calculated as Net Income divided by its Revenue. Unity Biotechnology's Net Income for the three months ended in Mar. 2025 was $-7.30 Mil. Unity Biotechnology's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, Unity Biotechnology's net margin for the quarter that ended in Mar. 2025 was 0.00%.

The historical rank and industry rank for Unity Biotechnology's Net Margin % or its related term are showing as below:


UNBX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

Unity Biotechnology  (OTCPK:UNBX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Unity Biotechnology Net Margin % Related Terms

Unity Biotechnology Net Margin % Historical Data

* Premium members only.

The historical data trend for Unity Biotechnology's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unity Biotechnology Net Margin % Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 -1,269.34 -18,842.80 0.00 0.00

Unity Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

UNBX vs ADTX, HEPA, EVFM: Net Margin % Comparison

For the Biotechnology subindustry, Unity Biotechnology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unity Biotechnology Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's Net Margin % distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's Net Margin % falls into.


Unity Biotechnology Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Unity Biotechnology's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-25.99/0
= %

Unity Biotechnology's Net Margin for the quarter that ended in Mar. 2025 is calculated as

Net Margin=Net Income (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-7.302/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Unity Biotechnology (UNBX) has a Net Margin % of 0.00% as of Mar. 2025. Net margin is the ratio of total net income to net sales. View historical data on Unity Biotechnology and its competitors.
Is Unity Biotechnology's Net Margin % too high?
Unity Biotechnology's current Net Margin % is 0.00%.
How does Unity Biotechnology's Net Margin % compare to ADTX and HEPA?
Unity Biotechnology's Net Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Unity Biotechnology and its competitors. Unity Biotechnology's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unity Biotechnology stock overvalued right now?
Unity Biotechnology (UNBX) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Unity Biotechnology (UNBX), the current Net Margin % is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unity Biotechnology Business Description

Address 285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.